FinnDiane LifeOne Study - Impact of Ageing on People With Type 1 Diabetes
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
- Кому может быть актуально
- Состояния в реестре: Diabetes Mellitus Type 1, Healthy Ageing. Базовые параметры: от 65 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Финляндия
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Обзор
Healthy aging refers to functional ability that enables well-being in older individuals. The focus thus shifts from chronological age to functional capacity and the individual's own experience of well-being. Type 1 diabetes is a chronic condition characterized by elevated blood glucose levels, which increases the risk of cardiovascular diseases and premature death. However, the life expectancy of individuals with type 1 diabetes has significantly improved due to advances in diabetes care. There is limited research on aging with type 1 diabetes, and this study is at the forefront of addressing this gap by examining aging-and especially healthy aging-in type 1 diabetes from multiple perspectives. The goals are to investigate how individuals with type 1 diabetes age and what their functional capacity is compared to individuals without insulin-treated diabetes. The other aim is to identify factors in midlife that predict healthy aging in people with type 1 diabetes.
Подробное описание
Ageing with type 1 diabetes is an emerging challenge due to improved life-expectancy of people with type 1 diabetes. While those who survive to an older age are considered survivors, the many years with type 1 diabetes and the chronic dysglycaemia inevitably also has negative health impacts on people living with this chronic disease. With scarce research in this area, ageing in type 1 diabetes has been identified as a research gap.
With this study, the aim is to assess the impact of ageing in people with type 1 diabetes via thorough characterization of older adults with type 1 diabetes, in comparison to matched controls. This will be accomplished through a comprehensive assessment of the participants' metabolic profile, body composition, vascular health, autonomic function, and a geriatric assessment focusing on the functional ability of the participants. In addition, this study will assess what type of challenges older adults with type 1 diabetes face regarding self-management, diabetes care, and daily life.
This study is a sub-study of the national Finnish Diabetic Nephropathy Study, initiated in 1997 and including adults with type 1 diabetes. Individuals over 65 living in the Helsinki capital area will now be invited for a regular FinnDiane study visit, as well as an additional visit for a geriatric assessment. The aim is to study 300 FinnDiane study participants and recruit a minimum of 100 matched controls. This cohort will be prospectively followed with a revisit after three to five years.
Первичные конечные точки
- Healthy ageing in people with type 1 diabetes mellitus [Срок оценки: From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.]
Вторичные конечные точки (5)
- Physical capacity [Срок оценки: From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.]
- Cognitive function [Срок оценки: From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.]
- Psychological well-being [Срок оценки: From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.]
- Vitality [Срок оценки: From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.]
- Sensory function [Срок оценки: From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.]
Критерии участия
Критерии включения
- Participants of the Finnish Diabetic Nephropathy Study
- Type 1 diabetes
- With age above 65 years
- Informed consent provided
Критерии исключения
- Age below 65 years
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Да
Дизайн исследования
- Модель наблюдения
- Случай-контроль
Центры проведения
Финляндия · 1 центр
- HUS Helsinki University Hospital — Helsinki
Идентификаторы
NCT: NCT07289204 · HUS/4387/2023